针对失眠的数字认知行为治疗在失眠患者中催眠减缓的有效性:一项随机对照试验
Min Liu1, Ruhan Yi2, Ziliang Han1
1Inner Mongolia Mental Health Center (The Third Hospital of Inner Mongolia Autonomous Region, Brain Hospital of Inner Mongolia Autonomous Region), Sleep Medicine Center, Hohhot, 010010, China.
失眠的数字认知行为疗法 (dCBT-I) 有效地减少了伴随性焦虑和抑郁症患者的催眠药物使用. 这种坚持友好的数字疗法为长期药物治疗管理提供了可行的替代方案.
科学领域:
- 精神病学是一个精神病学.
- 数字治疗学数字治疗学
- 睡眠医学 睡眠医学
背景情况:
- 失眠障碍通常与焦虑和抑郁症状同时发生.
- 患有这些并发症的患者经常需要长期的催眠药物治疗.
- 评估用于减少药物使用的数字干预措施至关重要.
研究的目的:
- 评估失眠数字认知行为疗法 (dCBT-I) 的有效性和坚持.
- 评估dCBT-I在减少伴随性焦虑和抑郁症患者的催眠药物的作用.
- 将dCBT-I与数字睡眠卫生教育 (dSHE) 进行比较.
主要方法:
- 一个随机,双盲,并行组试验,涉及112名成人门诊患者.
- 参与者接受了四周的dCBT-I或dSHE.
- 基于改善睡眠的催眠药物,使用逐渐逐渐减少的协议.
主要成果:
- 76名参与者完成了干预,其坚持率为74.5%.
- 与dSHE相比,dCBT-I在4,8和12周显示出显著的催眠药物减少.
- 对于有利于dCBT-I的药物减少,观察到统计学意义 (P <0.05).
结论:
- dCBT-I是一种有效的治疗方法,用于减少失眠和并发性焦虑/抑郁症状的患者的催眠药物治疗.
- 数字格式增强了坚持,并提供了一个实用的治疗模式.
- 这种方法支持在复杂的患者群体中减少药物使用.
更多相关视频
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
11:11Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
相关概念视频
Management of Insomnia
Insomnia
Multiple factors contribute...
Blind Procedures
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
CNS Depressants: Barbiturates and Benzodiazepines
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
